CereScape Pty Ltd
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
僅顯示目前所選商店地區的已觀測下載價格。點擊地區比價可查看各國家與地區的換算價格。
目前在 Apple 公開 App Store 頁面可見的項目,可能不等同於 App Store Connect 中的完整目錄。
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
根據最新觀測到的 App Store 資料快速解答。
最新觀測到的下載價格為 59.000đ。請開啟 App Store 官方連結確認目前結帳價格。
Apple 公開頁面目前在此商店顯示 0 個購買項目,公開清單可能不完整。
會。App Store 價格可能因商店、幣別、稅費和開發者定價而不同,目前已收集 1 個地區觀測。